Date:3/26/2009

Current assets Cash and cash equivalents $41,179 $34,989 Accounts receivable Trade, net of allowances of $5,357 and $5,313, respectively 121,736 148,045 Other 13,829 18,532 Inventories, net 87,867 108,914 Deferred income taxes 4,336 2,991 Due from Pactiv 1,399 7,072 Prepayments and other current assets 8,435 9,187 ----- ----- Total current assets 278,781 329,730 Property, plant and equipment, net 245,124 277,398 Other assets Goodwill 127,395 150,000 Intangible assets, net 41,254 47,910 Deferred financing costs, net 7,734 10,080 Due from Pactiv, long-term 13,234 12,229 Pension and related assets 22,430 25,659 Other 424 2,313 --- ----- Total other assets 212,471 248,191 ------- ------- Total assets $736,376 $855,319 -------- -------- Liabilities and stockholder's equity Current liabilities Current portion of long-term debt $4,902 $2,120 Accounts payable 79,092 100,326 Accrued income taxes 6,964 13,900
'/>"/>

SOURCE Pregis Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. Pregis Announces Investor Conference Call to Review Fourth Quarter and Full Year 2008 Financial Results
2. Pregis Announces Third Quarter 2008 Financial Results
3. Pregis Announces Investor Conference Call to Review 2008 Third Quarter Financial Results
4. Pregis Announces Second Quarter 2008 Financial Results
5. Pregis Announces First Quarter 2008 Financial Results
6. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
7. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
8. Pregis Corporation Appoints New President of Protective Packaging North America
9. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
10. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
11. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges